Eribulin mesylate
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sarcoma, Soft Tissue
Conditions
Sarcoma, Soft Tissue
Trial Timeline
Mar 1, 2016 → Nov 4, 2018
NCT ID
NCT03058406About Eribulin mesylate
Eribulin mesylate is a pre-clinical stage product being developed by Eisai for Sarcoma, Soft Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT03058406. Target conditions include Sarcoma, Soft Tissue.
What happened to similar drugs?
1 of 15 similar drugs in Sarcoma, Soft Tissue were approved
Approved (1) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03441360 | Phase 2 | Completed |
| NCT03583944 | Approved | Completed |
| NCT03361436 | Phase 1 | Active |
| NCT03437083 | Pre-clinical | Completed |
| NCT03058406 | Pre-clinical | Completed |
| NCT02481050 | Phase 2 | Completed |
| NCT02338037 | Phase 1 | Completed |
| NCT02171260 | Phase 1 | Completed |
| NCT03245112 | Pre-clinical | UNKNOWN |
| NCT01961544 | Approved | Completed |
| NCT01458249 | Phase 2 | Completed |
| NCT01463891 | Pre-clinical | Completed |
| NCT01328249 | Phase 2 | Completed |
| NCT01240421 | Pre-clinical | Completed |
| NCT01268150 | Phase 2 | Completed |
| NCT01269346 | Phase 2 | Completed |
| NCT01142661 | Pre-clinical | Completed |
| NCT01106248 | Phase 1 | Completed |
| NCT00965523 | Phase 2 | Completed |
Competing Products
20 competing products in Sarcoma, Soft Tissue